Use of bi-aryl meta-pyrimidine inhibitors of kinases

A method for inhibiting JAK2 kinase activity in a subject wherein the subject has rheumatoid arthritis comprising administering to the subject with rheumatoid arthritis a therapeutically effective amount of at least one compound represented by structure (A):

• wherein:
• X is selected from the group consisting of a bond, O, and CH2;
• Y is selected from the group consisting of a bond or NR9;
• or X and Y taken together is a bond;
• each R9 is independently selected from H and C1-C6 alkyl;
• each of R1 and R2 is independently selected from H and C1-C6 alkyl optionally substituted by halogen, amino or hydroxyl;
• each of p, q, and n is independently selected from 0, 1, 2, 3, 4, 5, and 6;
• G0 is N or CH,
• wherein when G0 is N, each of R3 and R4, taken together with G0, form a heterocyclic ring, wherein the formed heterocyclic ring is optionally substituted by one or two substitutents each independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, hydroxyl, or carboxyl, and
• and wherein when G0=CH, then R3 and R4, taken together with G0, form a heterocyclic ring wherein the formed heterocyclic ring is optionally substituted by one or two substitutents each independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 hydroxyalkyl, hydroxyl, or carboxyl;
• G is CR6′ where each R6′ is independent of each other group R6′;
• R6′ is selected from the group consisting of H, halogen, C(O)—O-alkyl, alkyl, alkoxy, and haloalkyl or R6′ is a bond when bonded to X;
• A is NR9;
• R5 is methyl;
• wherein each of R6, R7, R8 is independently selected for each occurrence from the group consisting of H, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, SO2H, SO2(C1-C6 alkyl), SO2-heterocycle, SO2-cycloalkyl, —SO2NH(C1-C6 alkyl), SO2N(C1-C6 alkyl)(C1-C6 alkyl), SO2NH(cycloalkyl), SO2NH-heterocycle, SO2NH(branched alkyl), NO2, CN, CONH2, CO—(C1-C6 alkyl), COOH, COO—(C1-C6 alkyl), and NHCO—(C1-C6 alkyl), or R6 and R7 taken together, or R7 and R8 taken together, or R6 and R8 taken together form a moiety independently selected from the group consisting of —CH═CH—CH═CH— and —O—(CH2)n—O—;
• G1 is CH;
• and
• G2 is CR7, with each group R7 being independent of every other group R7;
• or a pharmaceutically acceptable salt thereof.